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Design and rationale for examining
neuroimaging genetics in ischemic stroke
The MRI-GENIE study
ABSTRACT
Objective: To describe the design and rationale for the genetic analysis of acute and chronic cere-
brovascular neuroimaging phenotypes detected on clinical MRI in patients with acute ischemic
stroke (AIS) within the scope of the MRI–GENetics Interface Exploration (MRI-GENIE) study.
Methods: MRI-GENIE capitalizes on the existing infrastructure of the Stroke Genetics Network
(SiGN). In total, 12 international SiGN sites contributedMRIs of 3,301 patients with AIS. Detailed
clinical phenotyping with the web-based Causative Classification of Stroke (CCS) system and
genome-wide genotyping data were available for all participants. Neuroimaging analyses include
the manual and automated assessments of establishedMRI markers. A high-throughput MRI anal-
ysis pipeline for the automated assessment of cerebrovascular lesions on clinical scans will be
developed in a subset of scans for both acute and chronic lesions, validated against gold stan-
dard, and applied to all available scans. The extracted neuroimaging phenotypes will improve
characterization of acute and chronic cerebrovascular lesions in ischemic stroke, including
CCS subtypes, and their effect on functional outcomes after stroke. Moreover, genetic testing
will uncover variants associated with acute and chronic MRI manifestations of cerebrovascular
disease.
Conclusions: TheMRI-GENIE study aims to develop, validate, and distribute theMRI analysis plat-
form for scans acquired as part of clinical care for patients with AIS, which will lead to (1) novel
genetic discoveries in ischemic stroke, (2) strategies for personalized stroke risk assessment, and
(3) personalized stroke outcome assessment. Neurol Genet 2017;3:e180; doi: 10.1212/
NXG.0000000000000180
GLOSSARY
ADC 5 apparent diffusion coefficient; AIS 5 acute ischemic stroke; CE 5 cardioembolic; CCS 5 Causative Classification of
Stroke; CCSc 5 causative CCS; DICOM 5 Digital Imaging and Communications in Medicine; DWI 5 diffusion-weighted
imaging; DWIv 5 DWI volume; FLAIR 5 fluid-attenuated inversion recovery; GISCOME 5 Genetics of Ischemic Stroke
Functional Outcome; GWAS5 genome-wide association studies; ICC5 intraclass correlation coefficient; LAA5 large artery
atherosclerosis; MGH 5 Massachusetts General Hospital; MRI-GENIE 5 MRI–GENetics Interface Exploration; mRS 5
modified Rankin Scale; PHI 5 protected health information; QC 5 quality control; SAO 5 small artery occlusion; SiGN 5
Stroke Genetics Network; SNP 5 single nucleotide polymorphism; SWI 5 susceptibility-weighted imaging; TOAST 5 Trial of
Org 10172 Acute Stroke Treatment; VLSM 5 voxel-based lesion–symptom mapping; WMHv 5 white matter hyperintensity
volume; XNAT 5 eXtensible Neuroimaging Archive Toolkit.
Genome-wide association studies (GWAS) have been instrumental in elucidating the genetics of
complex vascular traits (ischemic stroke1,2 and coronary artery disease3,4) and their risk factors
(blood pressure,5 atrial fibrillation,6 hyperlipidemia,7 and diabetes mellitus8). Despite recent
advances in prevention and treatment, stroke remains a leading cause of adult neurologic
disability and death in the United States and worldwide.9 Recent GWAS have uncovered several
risk loci for ischemic stroke and its subtypes,10,11 specifically PITX2 and ZFHX3 for cardioem-
bolic (CE) stroke,11,12 HDAC911,12 and TSPAN211 for large artery stroke, and ALDH211 for
small artery stroke. These results highlight the necessity for large-scale collaborations such as
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METASTROKE and Stroke Genetics Net-
work (SiGN) to identify risk loci for these
complex diseases.
Improving our understanding of the mech-
anisms underlying stroke is crucial, as treat-
ment options remain limited for this
debilitating disease. Unlike clinical diagnosis
of stroke, cerebrovascular phenotypes detected
on brain MRI can be characterized with high
validity and quantified with good precision
using advanced neuroimaging analysis techni-
ques.13 Targeting these specific endopheno-
types will lead to substantial pathophysiologic
insight into stroke mechanisms and foster
future advances in individualized therapy and
prevention.
The MRI–Genetics Interface Exploration
(MRI-GENIE) study aims to bridge current
knowledge gaps by facilitating genetic discov-
ery and developing novel therapeutic and
preventive strategies in stroke through auto-
mated, multimodal MRI analysis. Leveraging
the existing infrastructure of SiGN and har-
nessing its expertise, MRI-GENIE focuses on
the subset of richly phenotyped and genotyped
participants for whom clinical MRIs have been
obtained. This article outlines the premises,
methodology, and aims of MRI-GENIE.
METHODS MRI-GENIE capitalizes on SiGN, an ongoing
multicenter, NIH-funded collaboration within the community
of stroke neurologists, geneticists, and neuroimaging analysts,
which enabled the initial development of the SiGN Imaging
Platform.14 We have amassed the largest-to-date collection of
ischemic stroke cases with comprehensively ascertained cerebro-
vascular phenotypes and genome-wide data. The project is fun-
ded by the NIH-NINDS (R01NS086905, N.R. Rost—PI) to
undertake the first major study to jointly model MRI-derived
traits obtained during acute ischemic stroke (AIS) evaluation,
causative and phenotypic stroke subtypes, and traditional vascular
risk factors to accelerate the pace of genetic discoveries and
advance clinical applications in risk and outcome prediction in
ischemic stroke.
Structure of MRI-GENIE. Participating study sites.
MRI-GENIE is founded on the existing collaborations between
members of the multidisciplinary clinical stroke research team
atMassachusetts General Hospital (MGH),Massachusetts Institute
of Technology (MIT), and the NINDS SiGN investigators.
To date, 12 sites from the initial SiGN study have contributed
phenotypes, images, and genotypic data of 3,301 participants to
MRI-GENIE (For a summary, see table and figure; detailed study
descriptions have been published previously11). Of those sites, 7 are
European centers (BASICMAR—Spain, BRAINS—United
Kingdom, GRAZ—Austria, KRAKOW—Poland, LEUVEN—
Belgium, LUND STROKE REGISTER—Sweden, and SAHLSIS
—Sweden) and 5 are based in the United States (GASROS,
GCNKSS, GEOS, ISGS, and MIAMISR). Informed consent of
study participants to data sharing was mandatory for all sites.
Shared data include basic demographics, vascular risk factors and
detailed Causative Classification of Stroke (CCS) phenotyping,
genotypic data, and clinical MRIs.
Study oversight. The primary aims and progress of the MRI-
GENIE study are overseen by a Scientific Steering Committee. In
conjunction with the SiGN Publication Committee, the MRI-
GENIE Steering Committee critically reviews project proposals
by collaborators to avoid potential overlap with existing SiGN
projects and to assess feasibility of the proposed projects. This
effort is supported by the Phenotyping Committee, which is in
charge of the data access to phenotypes previously obtained
through SiGN, current data acquisition for neuroimaging
markers, and quality control (QC) of new neuroimaging phe-
notypes. In addition, it is responsible for the oversight of statis-
tical analysis of MRI-derived phenotypes and functional
outcomes related to specific stroke subtypes. The Neuroimaging
Analysis Committee is in charge of designing, validating, and
implementing the MRI pipeline to automatically assess acute
and chronic neuroimaging markers. Moreover, it facilitates and
monitors the assessment of manually obtained neuroimaging
markers. The Genetic Analysis Committee conducts the primary
genetic analyses for the MRI-GENIE study to identify genetic
variants associated with acute and chronic MRI-based manifes-
tations of cerebrovascular disease. It is also essential in conducting
secondary analyses and additional projects as proposed by col-
laborators (detailed listings of committee memberships are
available in coinvestigator appendix e-1 at Neurology.org/ng).
Imaging platform. An integral part of the MRI-GENIE study
is the centrally maintained imaging platform hosting deidentified
acute or subacute brain MRIs obtained within 48 hours of
symptom onset from all contributing SiGN sites. The MRI-
GENIE Imaging Platform is maintained centrally at MGH and
has been described previously.14 Initially developed in the scope
of an NIH-funded project to create a centralized system to share
canonical human stroke data (R01 NS063925-01A1, O. Wu/
Sorensen—PI), the underlying technology for the imaging plat-
form integrates the eXtensible Neuroimaging Archive Toolkit
(XNAT)15 as the back-end data repository with a flexible, open-
source content management system with user-friendly features
(conglomeration of Plone,16 Deliverance,17 and NGINX18) as the
front end for the users. An example of such features is the ability
to search the imaging repository by stroke-specific clinical phe-
notypic variables (e.g., age, sex, or infarct location). Images can be
viewed for semiquantitative analysis via a web-based XNAT
plugin.15
Upon receipt of MRIs from the individual sites in the “Digital
Imaging and Communications in Medicine” (DICOM) format,
all images were deidentified to remove protected health informa-
tion (PHI) potentially embedded into the DICOM headers. In
addition, DICOM files with image type indicative of screen shots
were removed to ensure elimination of files with potential PHI
that may be “burned” into the screen shots. Each site provided
phenotypic data (e.g., SiGN ID, sex, race, ethnicity, age, and
infarct location). Age and sex were cross-referenced with pheno-
types documented in the SiGN Phenotype Database, to flag
potential discrepancies between databases.
The imaging platform is open to collaborators for the explo-
ration of phenotypic and genetic underpinnings of AIS. Individ-
ual investigators receive access in a project-based manner, after
the MRI-GENIE Scientific Steering Committee and the SiGN
Publication Committee have reviewed the project proposal.
Incorporating the computational workflow for automated seg-













the imaging platform will complete the process for centralized
data abstraction, collection, and sharing for future genetic studies.
MRI-derived phenotypes. The analysis of MRI-derived phe-
notypes will include both automated, volumetric analyses as well
as manual, semiquantitative analyses of acute and chronic cere-
brovascular phenotypes.
Image preprocessing. Prior to phenotypic analyses, imaging
data from some sites required a manual review. As part of the de-
identification process, some sites removed all metadata informa-
tion from the DICOM headers, including series description,
prior to transmission of images. This necessitated a visual review
of cases by a trained operator for sites for which no series descrip-
tions were available. For these sites, sequence labels for T2 fluid-
attenuated inversion recovery (T2 FLAIR), diffusion-weighted
imaging (DWI), susceptibility-weighted imaging (SWI), and
magnetic resonance angiography were ascertained. Although the
quality of specific sequences may preclude future analysis of
specific phenotypes, no participants were excluded for image
quality reasons (e.g., motion artifact and low-quality images) or
incomplete imaging data (e.g., missing FLAIR sequence) at this
stage to maximize the overall sample size in analysis of individual
phenotypes. For manual semiquantitative analyses, useful infor-
mation can often be extracted (e.g., location of acute infarct) by
expert image analysts despite artifacts (e.g., motion).
Image QC. Image sequences will be excluded from auto-
mated and semiquantitative analysis based on visual inspection
due to excessive motion artifact, incomplete sequence acquisition,
or severe bilateral brain pathology that precludes accurate assess-
ment. Details of the MRI data acquisition that are embedded in
the DICOM headers (e.g., MRI manufacturer, model name, field
strength, dimensions, echo time, and repetition time) will be re-
tained to allow for subset analysis of phenotypic information as
a function of data acquisition variability.
Quantitative analyses of acute and chronic neuroimaging
markers. The acute infarct volume measured on DWI will be
analyzed through an automated segmentation algorithm.19,20
The algorithm will be trained on an independent cohort of acute
stroke data and then applied to MRI-GENIE participants. The
results will be validated across sites against a random sample set of
images selected from each site for which manual lesion volumes
will be drawn. The automatically determined acute DWI volume
(DWIv) will be used to evaluate the effect of stroke lesion volume
and topography on poststroke outcomes. Voxel-based lesion–
symptom mapping (VLSM) has been used previously to investi-
gate the relationship between ischemic stroke lesion location and
stroke severity and outcome, but so far has been limited to the
middle cerebral artery territory. The sample size of MRI-GENIE
will allow for investigating all vascular territories with VLSM.21
The pre-existing burden of cerebrovascular white matter dis-
ease, measured as white matter hyperintensity volume (WMHv),
will be computed by a separate automatic analysis algorithm
based on T2-FLAIR images.22 Key components of the WMH
analysis will be the registration of all T2-FLAIR images to a com-
mon atlas space and segmentation of WMH based on the voxel
intensity information and spatial priors that pattern WMH in the
brain.23 The algorithm will be trained on manually outlined
WMH segmentations. Validation across sites will be performed
for each site on a random sample of scans representing the entire
severity spectrum of WMH.
QC of automated, quantitative phenotypes. The results of
automatic acute DWI and WMH lesion analysis will be cross-
validated with manually drawn lesion volumes obtained on
a random subset of scans from each site representative of the
disease spectrum. Intraclass correlation coefficient (ICC) will be
used to assess the agreement between the manual and the auto-
mated volumes. Further evaluation of the automated algorithms
will involve voxel-based comparison of the automated masks with
manual outlines and classifying true positives, true negatives, false
positives, and false negatives. Performance of the automated al-
gorithms will be assessed by analysis of sensitivity, specificity, and
Dice similarity coefficient.24 Subset analysis of algorithm accuracy
as a function of MRI data acquisition parameters will be per-
formed to assess for bias as a function of scanner data quality.
Semiquantitative analysis of acute and chronic neuroimaging
markers. MRIs will be systematically reviewed for acute and chronic
markers of cerebrovascular disease to facilitate topography-based and
stroke subtype–specific analyses. Specific data sets may be excluded
on a case-by-case basis if artifacts preclude an accurate reading. DWI
will be used to ascertain acute infarct location (vascular territories:
middle cerebral artery, anterior cerebral artery, posterior cerebral
artery, vertebrobasilar artery, and multiple vascular territories),
Table Basic demographic data for the MRI-GENIE study sites (n 5 12)





BASICMAR IMIM-Hospital del Mar, Spain 124 69.8 6 11.0 37.1 94.4
BRAINS Imperial College—London, UK 70 63.2 6 16.4 47.1 94.3
GASROS Mass General Hospital 457 64.9 6 14.5 35.4 93.2
GCNKSS U Cincinnati 245 64.3 6 14.3 49.0 72.7
GEOS U Maryland 76 41.8 6 6.5 26.3 52.6
SAHLSIS U of Gothenburg—Sweden 401 52.4 6 11.7 38.7 100
GRAZ Medical University—Graz, Austria 373 63.3 6 13.7 30.0 100
ISGS Mayo Clinic—Florida 425 65.1 6 14.7 40.9 84.2
KRAKOW Jagiellonian University—Poland 224 60.5 6 13.9 46.4 100





196 63.4 6 12.8 39.3 100
MIAMISR U Miami 262 62.1 6 13.8 37.0 59.5
Abbreviation: MRI-GENIE 5 MRI–GENetics Interface Exploration.
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number of acute infarct lesions, and DWI-based stroke subtypes
(cortical, subcortical, and watershed infarct). When available,
maps of the apparent diffusion coefficient (ADC) will be cross-
referenced to minimize inclusion of lesions that are not pertinent
to the index stroke. This is necessary because in the subacute to
chronic stage, within hyperintense DWI lesions, the corre-
sponding ADC values may be pseudonormal or elevated as
a result of vasogenic edema.25 T2-FLAIR sequences will be used
to screen for subacute and chronic infarcts, as well as WMH
severity using the Fazekas scale.26 Cerebral microbleed (CMB,#
10 mm) count and location, macrohemorrhages (.10 mm),27
and hemorrhagic infarct transformation will be rated on 2D T2*
gradient echo or 3D SWI sequences. In addition, the location of
arterial occlusion, collateral circulation grade, and evidence of
significant extracranial or intracranial large artery stenosis will be
evaluated on MR angiography.
QC of semiquantitative phenotypes. Readers will be system-
atically trained on a standardized training set of AIS MRIs to
attain the independent rater status (e.g., Fazekas score or CMBs).
Furthermore, agreement between raters will be evaluated with the
ICC for ordinal and continuous data, and a Cohen kappa will be
used to assess interrater agreement for categorical data.
AIS subtyping. All patients with AIS in SiGN underwent exten-
sive phenotyping through the web-based, standardized algorithm
“Causative Classification of Ischemic Stroke” (details on CCS
phenotyping in SiGN have been previously published).14 In brief,
CCS incorporates multiple clinical symptoms, clinical examina-
tions, and testing results obtained throughout the clinical stroke
evaluation and assigns both a phenotypic CCS subtype based on
abnormal testing results at the time of stroke and causative CCS
(CCSc) subtyping based on prior medical history. If challenged
with multiple potential causes of ischemic stroke, CCSc assigns
the most likely cause of stroke based on clinical data. CCSc al-
locates one of 5 different causative and phenotypic subtypes based
on symptoms, vascular risk factors, and diagnostic tests. The 5
major categories are large artery atherosclerosis (LAA), small
artery occlusion (SAO), CE stroke, other, and undetermined
causes of stroke. Known rare causes of ischemic stroke were
excluded fromMRI-GENIE. The exact workup was performed as
clinically directed by individual study centers. This includes pa-
tients with rare monogenic causes of stroke (cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoence-
phalopathy, mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes, and sickle cell syndrome), infectious
causes (infective endocarditis, meningitis, and primary infection
of the arterial wall), hypercoagulability (acute disseminated
intravascular coagulation and heparin-induced thrombocytopenia
type II), distinct vascular and cardiac disorders (acute arterial
dissection, dilated cardiomyopathy, papillary fibroelastoma, left
atrial myxoma, and cerebral venous thrombosis), as well as
migraine-related, drug-induced, or iatrogenic causes of ischemic
stroke.
In addition to CCS, Trial of Org 10172 Acute Stroke Treat-
ment (TOAST)28 subtyping was conducted by the sites if
required by the individual study protocols. Ischemic stroke cases
are assigned to the most likely cause of stroke: LAA, SAO, CE,
other, or undetermined. In SiGN, CCS and TOAST agree mod-
erately (agreement rate 70%), varying by site and stroke subtype
with LAA having the highest agreement across CCS and TOAST
and SAO having the lowest agreement rate.29 TOAST subtyping
will be valuable in instances if future replication cohorts will not
have appropriate CCS subtyping.
Functional outcomes and clinical characteristics. Baseline
stroke severity was assessed using the NIH Stroke Scale,30,31
and the modified Rankin Scale (mRS)32 was used to assess func-
tional outcomes at 3–6 months after stroke in a subset of the
SiGN sites. These data will be available through collaboration
with the Genetics of Ischemic Stroke Functional Outcome
(GISCOME) study. The mRS measures the degree of depen-
dence and disability after neurologic injury, ranging from
Figure Organizational structure of MRI-GENIE
MRI-GENIE 5 MRI–GENetics Interface Exploration; SiGN 5 Stroke Genetics Network.
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0 (asymptomatic) to 6 (death). Other clinical baseline character-
istics were collected per protocol of the individual studies.
Genotyping and analysis strategy. Stroke cases were either
genotyped previously and genotypes submitted to SiGN, or they
were genotyped as part of SiGN, at the Center for Inherited Dis-
ease Research on the Illumina HumanOmni5Exome-4v1 array.14
This platform includes 4.5 million single nucleotide poly-
morphisms (SNPs) genotyped across the genome, resulting in
excellent coverage of both common and infrequent variants
(.1%). In addition, 240,000 rare polymorphic variants (#1%)
were genotyped. The majority of cases are of European ancestry
(table), but a small number of African Americans (n 5 249, self-
reported) and Hispanics (n5 153, self-reported) are available for
analysis. The SiGN Data Management Core has undertaken the
data cleaning and QC procedures for the primary analysis in
SiGN. QC procedures included data cleaning by subjects with
removal of samples with (1) a poor genotyping rate (,98%), (2)
identity problems (sex mismatch, unexpected duplicates, and
cryptic relatedness), (3) chromosomal anomalies, (4) batch ef-
fects, and (5) ethnic outliers. Poor-quality SNPs were identified
on the basis of high levels of missingness. The cleaned data are
maintained at the SiGN Data Management Core. The analysis
plan for the MRI-GENIE portion of SiGN includes a principal
component analysis to identify and account for population
stratification in subsequent genome-wide association testing.
Genotype imputation has been performed on the University of
Michigan Imputation Server (imputationserver.sph.umich.edu/
index.html)33 using the Haplotype Reference Consortium
panel.34 The primary genetic analysis will be to test for the
association of SNPs with the DWI and WMH volumes. The
association analyses will be performed under a linear regression
model with allelic dose (0, 1, or 2 copies of the reference allele) as
the independent variable adjusted for age, sex, and population
stratification as calculated by principal component analysis. DWI
and WMH volumes will be adjusted for average head size and
natural log transformed to facilitate modeling with linear
regression because of nonlinear volume distributions. The current
sample size of 3,301 participants will provide 80% power to
detect variants accounting for as little as 1.2% of the variation in
DWI or WMH at genome-wide levels of statistical significance (i.
e., p , 5 3 1028). Secondary analyses will include the modeling
of CCS subtypes and ethnic group–specific analyses. SNPs found
to be associated with WMHv and/or DWIv will be tested for
association with 90-day mRS data available in the GISCOME
study. Additional analyses will be performed to examine stroke
subtype–specific genetic effects on DWIv and WMHv as well as
the genetic underpinnings of additional neuroimaging markers.
Incoming sites. In the spirit of open collaboration, the MRI-
GENIE Imaging Platform is available to collaborators. We are
currently incorporating 8 new sites (estimated additional total
n 5 3,890) including (1) Secondary Prevention of Small Sub-
cortical Strokes, n z 1,000, (2) Siblings With Ischemic Stroke
Study, n z 300, and (3) Washington State University–St. Louis
stroke patient collection, nz 640, (4) Helsinki-2000 study, nz
300, (5) Australian Stroke Genetics Cohort, nz 100, (6) Stroke
in Young Fabry Patients, n z 800, (7) University of Campinas
stroke patient collection, n z 150, and (8) Follow-up of Tran-
sient Ischemic Attack and Unelucidated Risk Factor Evaluation
Study/Observational Dutch Young Symptomatic StrokE studY,
n z 600. These collaborations will lead to the development of
one of the largest (nz 7,000) databases of patients with ischemic
stroke with MRI and genome-wide genotyping available to date.
CONCLUSIONS Quantitative neuroimaging has
recently been used to gain further insight into physi-
ology and anatomy in both healthy participants (e.g.,
intracranial volume35) and clinical cohorts (e.g., hip-
pocampal volumes36 and structural neuroimaging bi-
omarkers37 in Alzheimer disease). In this article, we
aim to analyze acute (e.g., cerebral infarct volume)
and chronic (e.g., WMH volume and cerebral micro-
bleeds) neuroimaging phenotypes in patients with
AIS. While genetic loci associated with WMH have
previously been reported in healthy populations,38,39
no loci associated with WMH have yet been identi-
fied in patients with AIS, despite efforts with large
sample sizes.40 Similarly, no studies have linked spe-
cific genetic loci with cerebral microbleeds or stroke
lesion volume. To facilitate these genetic studies,
MRI-GENIE will develop, validate, and disseminate
an automated analysis pipeline for large-scale phe-
notypic analysis of clinical brain MRI, as part of the
future advances in personalized prediction modeling
of stroke risk and outcomes.
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